Setipiprant and its Impurities

Setipiprant is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. Reference standards of Setipiprant API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.